Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(03): 134-136
DOI: 10.4103/sajc.sajc_160_16
ORIGINAL ARTICLE : Melanoma and Skin Cancer

Experiences of two different modalities in the management of choroidal melanoma in the Asian Indian population

Prajna Meeralakshmi
PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu
,
Parag K. Shah
Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu
,
Venkatapathy Narendran
Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu
› Author Affiliations Financial support and sponsorship: Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Background: Choroidal malignant melanoma is a rare intraocular cancer in Asian Indian population. There is a paucity of data from our population comparing iodine 125 (I-125) brachytherapy and enucleation. Aim: This study aims to compare two groups of choroidal melanoma patients treated with either I-125 brachytherapy or enucleation in the Asian Indian population. Objectives: To evaluate the long-term morbidity and mortality rates in choroidal melanoma patients treated with either I-125 brachytherapy or enucleation. Methods: It is a retrospective study involving forty four eyes, diagnosed with choroidal melanoma from May 2008 to February 2015. All were evaluated preoperatively for metastasis. Twenty-two underwent globe salvaging I-125 brachytherapy surgery whereas remaining 22 underwent globe destructive primary enucleation procedure. Results: At a mean follow-up 39 months, 2 of 22 cases (9%) died in the brachytherapy group. One was secondary to metastasis in the liver while the other case died of a natural cause. In the enucleation group also, there were two deaths (9%) secondary to metastasis. The metastasis free survival was 95% in the brachytherapy group and 91% in the enucleation group, which was not statistically significant (P = 0.3577). Kaplan–Meier survival at 3 years and 5 years was 95% and 89% for brachytherapy group and 94% and 89% for enucleation group. Conclusion: This study found no difference in the long-term survival of choroidal melanoma patients treated with either brachytherapy or enucleation in the Asian Indian eyes.

Key words

Choroidal melanoma - enucleation - India - iodine 125 brachytherapy


Publication History

Article published online:
22 December 2020

© 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Shields JA, Shields CL, editors. Posterior uveal melanoma: Clinical features. In: Intraocular Tumors. An Atlas and Textbook. 3rd ed. Philadelphia: Lippincott Wolters Kluwer; 2016. p. 95-127.
  • 2 Seddon JM, McCannel TA. Epidemiology of posterior uveal melanoma. In: Ryan SJ, Sadda SR, Hinton DR, Schachat AP, Wilkinson CP, Wiedemann P, editors. Retina. New York: Elsevier Saunders Inc.; 2013. p. 2231-7.
  • 3 Singh AD, Turell ME, Topham AK. Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 2011;118:1881-5.
  • 4 Raivio I. Uveal melanoma in Finland. An epidemiological, clinical, histological and prognostic study. Acta Ophthalmol Suppl 1977;133:1-64.
  • 5 Birdsell JM, Gunther BK, Boyd TA, Grace M, Jerry LM. Ocular melanoma: A population-based study. Can J Ophthalmol 1980;15:9-12.
  • 6 Osterlind A. Trends in incidence of ocular malignant melanoma in Denmark 1943-1982. Int J Cancer 1987;40:161-4.
  • 7 Manohar S, Ramakrishnan R, Das TP, Namperumalsamy P. Malignant melanoma of choroid. Indian J Ophthalmol 1991;39:70-3.
  • 8 Biswas J, Krishnakumar S, Shanmugam MP. Uveal melanoma in Asian Indians: A clinicopathological study. Arch Ophthalmol 2002;120:522-3.
  • 9 Shah PK, Selvaraj U, Narendran V, Guhan P, Saxena SK, Dash A. Indigenous (125)I brachytherapy source for the management of intraocular melanomas in India. Cancer Biother Radiopharm 2013;28:21-8.
  • 10 Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS report no. 18. Arch Ophthalmol 2001;119:969-82.
  • 11 Design and methods of a clinical trial for a rare condition: The collaborative ocular melanoma study. COMS report no. 3. Control Clin Trials 1993;14:362-91.
  • 12 Dhupper M, Biswas J, Gopal L, Kumar SK, Khetan V. Clinicopathological correlation of choroidal melanoma in Indian population: A study of 113 cases. Oman J Ophthalmol 2012;5:42-5.
  • 13 Kashyap S, Venkatesh P, Sen S, Khanduja S, Shrey D, Tinwala S, et al. Clinicopathologic characteristics of choroidal melanoma in a North Indian population: Analysis of 10-year data. Int Ophthalmol 2014;34:235-9.
  • 14 Sengupta S, Krishnakumar S, Biswas J, Gopal L, Khetan V. Fifteen-year trends in indications for enucleation from a tertiary care center in South India. Indian J Ophthalmol 2012;60:179-82.
  • 15 Khetan V, Gopal L, Shanmugam MP, Gupta A, Sharma T, Bhende P, et al. Brachytherapy of intra ocular tumors using 'BARC I-125 Ocu-prosta seeds': An Indian experience. Indian J Ophthalmol 2014;62:158-62.
  • 16 Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002;109:2197-206.
  • 17 Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology 2003;110:2223-34.
  • 18 Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology 2001;108:348-66.
  • 19 Histopathologic characteristics of uveal melanomas in eyes enucleated from the collaborative ocular melanoma study. COMS report no. 6. Am J Ophthalmol 1998;125:745-66.
  • 20 Houston SK, Shah NV, Decatur C, Lonngi M, Feuer W, Markoe AM, et al. Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment. Clin Ophthalmol 2013;7:193-8.